We pay docs more — sometimes very much more — than other countries do

Primary care physicians (PCPs) in the United States earn the highest incomes — higher than in five other developed countries, reports a new study in Health Affairs. But that scale is relative, given the costliness of the overall U.S. health care system, the researchers caution. Lead author Miriam J. Laugesen, assistant professor of health policy and management at the Mailman School of Public Health at Columbia University, says, “All countries are struggling with the growth of health care costs but it’s the higher fees ... that public and private payers paid that is significant.” PCPs in the United States were paid an average of 27 percent more by public payers for an office visit, and 70 percent more by private payers for an office visit, in comparison with the average paid in the other countries.

The study also reviewed earnings of orthopedic surgeons. Researchers found a similar pattern, with specialists in the U.S. earning the highest pretax incomes, net of expenses.

Physician earnings in six countries, 2008

Note: All earnings figures were converted to U.S. dollars and adjusted for purchasing power parity and then converted to 2008 dollars using the U.S. Consumer Price Index.

Source: Laugesen MJ, Glied SA. Higher fees paid to U.S. physicians drive higher spending for physician services compared to other countries. Health Aff. 2011;30(9):1647–1656

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.